期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 93, 期 1, 页码 26-28出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2012.207
关键词
-
资金
- National Institutes of Health (NIH) [HL113264, HL075478, HL105339, HL089856, HL083069, HL061795, HL048743, HL107192, HL070819, HL108630]
- NHLBI
- GlaxoSmithKline
- AstraZeneca
- Merck
Although impressive advances have been made in determining the genetic and molecular causes of disease, treatment for many complex diseases remains inadequate. Despite compelling unmet medical needs and new insights into disease pathobiology, new drug approvals for complex diseases have stagnated. A new paradigm for drug development is needed, and key concepts from network medicine and systems pharmacology may be essential to this effort.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据